December 10th & 11th, 2026
15th edition
MARSEILLE, FR

Exploring the pharma-VC relationship: How do they build complementary investment strategies?

Edition

Exploring the pharma-VC relationship: How do they build complementary investment strategies?

Pharma and VC firms have a symbiotic relationship, with VCs providing crucial funding to startups, and pharmaceutical companies offering strategic partnerships and potential acquisition opportunities. How do they align their investment strategies to maximize mutual benefits? How do pharma and VC firms manage their differing risk appetites and investment timeframes? What approaches do pharma and VC firms take to due diligence and decision-making processes? What is the place for the corporate VCs in the relationship?

Moderator: Bart Wuurman, CEO, Apaxen

Florence Dal Degan

Senior Director, External Innovation
Ipsen

Maya Chkaiban

Associate
Jeito

Nuno Alves

Associate Director, Innovation Management
Astellas Europe

Tugrul Ozdemir

Associate
Novo Holdings
Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.